2019 Healthcare That Works for All
|
|
- Wilfrid Gilmore
- 5 years ago
- Views:
Transcription
1 2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in Each paper focuses on one aspect of healthcare. To see the other papers for a comprehensive view of systems change, go to Science & Technology Base in 2019 Science & Technology That Works for All Fostering Science & Technology for a Better Future Requires: 1. Value based Evaluation of New Technologies To Address Risks and Benefits 2. Strong Support for Science Education and Interdisciplinary Research 3. Moving Upstream Towards Prevention 4. Furthering Personalization of Risk Assessment for Targeted Medicine 5. Leveraging New Methods of Open Source Collaboration A New Approach to Research & Development Improving our healthcare system will require a new approach to research and development that is more open and interdisciplinary. This approach to research and development will broaden as it aligns with values, public policies and signals from the free market. Science can contribute more to health by focusing on preventing sickness, controlling costs, improving efficiency, and developing therapies for neglected and high disparity diseases. The resulting breakthroughs from science and technology are going to come from more sources because the global population of educated people will gain greater access to knowledge that can be applied to improve health. Some basic paradigms will also change as the culture of science expands to integrate social sciences, which will help address community health, prevention and disease management. By combining traditionally separate soft and hard science researchers will better understand the complex interrelationships between environment, social interactions and biology. Recent research already shows that events in early life, even starting during pregnancy, can alter gene expression by a process called epigenetics. Newly released studies support the idea that these epigenetic changes, which alter gene expression, can be passed on from parents to future generations. This dynamic appears to be an underlying factor in our worsening epidemics of obesity and diabetes, and we may not be able to Science & Technology Base in Web Final
2 reverse the trends without making fundamental changes in our environment and social forces. Mental health disorders, some cancers and other disease also appear to involve epigenetic dynamics. The environment and social determinants of health, which currently receive little research attention, will turn out to be critically important. So new genetic knowledge could point the way for how we must change our environment, personal behavior and society as a whole to maintain a healthy nation. This knowledge will weaken long standing boundaries between scientific disciplines and other forms of understanding, including various cultural worldviews and religions that are studied in the social sciences. The new scientific agenda will be propelled by centers emerging in China, India and other areas that will be linked by better tools for online collaboration. These tools will allow researchers to interact in real time in virtual worlds to share ideas and test hypothesis. These new forms of collaboration will change the cultural silos of the global scientific community by including more eastern values and focusing on scientific problems of concern to the developing world. This cultural shift will make prevention, neglected and high disparity diseases paramount concerns for science. The ethos and methods of open source will propel the free flow of ideas and reverse the propensity to over patent and restrict basic research, which has been an unintended consequence of the 1980 Bayh Dole Act. More open, collaborative projects that involve multiple research centers from around the world will define much of the big basic science occurring globally. These projects will follow the footsteps of earlier collaborations such as the Human Genome Project and International HapMap Project. Other projects, such as the Biological Innovation for an Open Society (BIOS), and the Public Library of Science (PLoS), will explicitly draw on the ethos, community building methods, and I.P. protections of the open source community in software to create an intellectual commons of scientific knowledge that researchers can draw upon. Scientists and policy makers alike will be operating in a more democratic and transparent world that moves toward interdisciplinary approaches and holistic views. The most effective way to improve health and lower healthcare costs requires biomedical scientists and social scientists to collaborate in finding solid links between lifestyle, environment, society and health. Together biomedical and social scientists can create the tools needed by policy makers to improve health by using community based interventions. Both scientists and policy makers will be supported by new biomonitoring technologies and health information systems that provide real time tracking of health information. Policy makers will also need to revamp regulation in the healthcare sector to take advantage of new technologies, reduce costs and improve safety. For example, in drug development, much of the costs are caused by lengthy and expensive clinical trials that provide very partial information regarding safety and efficacy. Relatively rare safety problems that are unlikely to be found in clinical trials can be more effectively found in markets given a new infrastructure of electronic medical records, biomonitors and linked scientists who study data in open source networks. Reducing the costs of drug development will also require the use of new methods such as adaptive clinical trials to more quickly identify promising drug candidates, eliminate those with safety problems, and identify sub populations of patients for whom specific drugs will be the most beneficial. However, these changes will work only with increased Science & Technology Base in Web Final
3 support for regulatory agencies so they have the knowledge needed to use new methods and technology. Better computer simulations and advances in molecular biology will also make it easier for both regulators and drug companies to identify promising candidates early in clinical trials and eliminate those most likely to fail. They will also make it easier to identify sub populations most likely to benefit. These same technologies will also be used to further identify and narrow down sub populations most likely to see benefit from any given treatment. Forecast for Science & Technology Breakthroughs Advances in science & technology in 2019 illuminate not only the importance of molecular changes inside the cell, but the complex and interactive systems that affect health. Advances in the omic sciences (e.g. genomics, epigenomics, proteomics, metabolomics, etc.) provide a basis for understanding the complex interactions inside the human body that predict disease. By 2019, systems biology will contribute to better measures of risk for disease as well as better diagnostic tests for monitoring and managing health. Genomics in 2019 heralds a form of personalized medicine where diagnostic tests are used to identify treatments most likely to help a patient. This includes personalized lifestyle and nutrition changes focused on preventing disease and supported by biomonitoring technologies. Proteomics, metabolomics and other omic sciences are a vital part of this move toward personalized medicine as they provide new targets for therapies and diagnostic devices. Epigenomics provides the link between personal genomics and effective prevention by illuminating the relationship between genetics and social, environmental and lifestyle changes. Systems biology, a scientific discipline that studies the complexity in biological systems, combines these disciplines together and allows researchers to understanding how complex systems work inside the cell and the importance of environmental and social influences. Preventing disease by making major changes in the way we live could be the bedrock of future health management. Nanotechnology supports advances in the omic sciences and systems biology and is an integral part of new diagnostic tests and therapies in The ability of nanotechnology to create new molecules and manipulate existing molecules is widely used in developing new diagnostics and therapies. Nanotechnology allows medical device companies to alter the surface of materials enabling, for example, companies to create smaller implants, artificial organs with pores at the nanoscale and implants that bind with tissue faster. Quantum dots and other nano particles improve imaging technologies by enabling better visualization and image guided therapies. Micro fluidic nanolabs are developed that are capable of measuring key interactions within individual cells and aggregating those measurements for hundreds of thousands of cells. Science & Technology Base in Web Final
4 In 2019, patients will track their own health using biomonitoring technologies and work with automated programs to improve their lifestyles. Advances in high throughput screening allow patients to receive a full, personal genome for under a $1, Other biomarker tests enable patients to monitor the level of a wide range of proteins, metabolites and other molecules in the body. Consumer devices enable the health conscious to accurately track calorie input and energy expenditure as well as exposure to environmental toxins. Inexpensive wireless broadband enables these devices to share information with patient s cell phone or computer. Patients can then store that information in robust personal health records that allow them to track vital statistics over time to monitor their own health. This data will be shared with patients care teams so they can accurately determine genetic risk for certain types of diseases, how well they are doing in managing their diseases, reacting to therapy or improving their lifestyles. A Successful Innovation System For Healthcare In 2019 The healthcare innovation system of 2019 balances the tension between generous support for health science research and the growing funding crisis in healthcare. Many of the new technologies and therapies in healthcare that will emerge in 2019 will be extraordinarily expensive. They will also save or improve the lives of millions. To manage that balance, the healthcare payment and delivery systems of 2019 focus on prevention and using safe, effective interventions. These changes send the right market signals to the companies that develop new technologies and therapies. The changes are consistent with the changes identified as needed in our healthcare system as outlined in IAF s payment and delivery system briefs as well as the values for healthcare identified by the 2019 Healthcare that Works for All. While the costs of maintaining world leadership in research and development in 2019 remains high, the United States receives more health benefit for each dollar spent by focusing on prevention, using new technologies for pre and post market studies, embracing adaptive clinical trials and targeting therapies to those sub populations most likely to receive benefit. Many of the cost savings come by restricting access to technologies and therapies that do not help a patient, or lead to expensive complications with therapeutic failures. These changes in incentives for science and technology are achieved by the market focused incentives and pressure by stakeholders as outlined in the health economics brief. The 2019 healthcare system links science and health through partnerships with local communities on effective public health and disease prevention initiatives. Government agencies work together to address the underlying causes of health inequities such as sub standard housing, environmental pollutants, inadequate transportation and institutional racism. Large scale studies on community health, using the information gathered by the personal health records of community members, provide policymakers with concrete evidence to justify expenditures in public health and disease prevention. These new strategies not only reduce morally unjust health inequities, but also reduce healthcare costs by reducing expensive care for preventable chronic diseases and high cost acute care at emergency rooms where technology is put to work at a very high cost. Science & Technology Base in Web Final
5 Pragmatic Steps To Achieve This Vision Of A Better Future A. Continued support for basic research B. More support for applied and post market research C. Strong patent protections combined with innovations from open source D. Shift to adaptive clinical trials combined with strong post market studies E. Improved funding for regulatory agencies to build up capacity in new science and technology F. New funding and innovation approaches for neglected and high disparity diseases G. More funding on the socioeconomic links to poor health H. Better alignment in healthcare payment and delivery systems with prevention to provide the right market forces for innovation What Would Happen If We Fail To Change? Failure to change our system of innovation promises to undermine public support for science and technology. If dazzling and expensive science serves the interests of a few while failing to improve the health of many, the ethical base of medical innovation will erode, and the large budgets provided NIH and the patents granted to industry will come under attack. Public outrage over preventable harm from therapeutic failure will lead to a rejection of high tech medicine and adoption of alternative therapies. America has been spending over $2 trillion a year in the healthcare sector of our economy. One of the benefits of this tremendous expense has been access to the most cutting edge technology and therapies in the world for those with good health coverage. However, to continue to provide access to this cutting edge technology requires the U.S. to focus on developing, and paying for, only the most efficacious therapies. This must be combined with upgrades to our health information systems to ensure patients, physicians and researchers have access to timely and accurate health information. In the coming era of tight federal and state budgets, there will also be the temptation to cut back on the basic research that fuels innovation. And there will always be political pressure to restrict research in ethically grey areas such as stem cells. Both pressures must resisted least the locus of innovation, and high quality jobs, that currently reside in the United States move abroad. Science & Technology Base in Web Final
How To Change Medicine
P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version
A leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
The National Institute of Genomic Medicine (INMEGEN) was
Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the
Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision
Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision Medicine Initiative: Building a Large U.S. Research Cohort
Draft NIEHS Strategic Plan. Mission, Vision, Strategic Pillars, Strategic Goals. Draft Mission Statement
Draft NIEHS Strategic Plan Mission, Vision, Strategic Pillars, Strategic Goals Draft Mission Statement The mission of the National Institute of Environmental Health Sciences is to discover how the environment
Exploratory Brief on Nanomedicine or the Application of Nanotechnology in Human Healthcare
Exploratory Brief on Nanomedicine or the Application of Nanotechnology in Human Healthcare Paula Corabian, Dagmara Chojecki March 6, 2012 Objectives Provincial Health Technology Assessment (HTA) Program
THE LINCOLN INSTITUTE OF HEALTH
THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges
2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
Principles on Health Care Reform
American Heart Association Principles on Health Care Reform The American Heart Association has a longstanding commitment to approaching health care reform from the patient s perspective. This focus including
New York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
The NIH Roadmap: Re-Engineering the Clinical Research Enterprise
NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by
The. for DUKE MEDICINE. Duke University School of Medicine. People
The for DUKE MEDICINE Decades of hard work by dedicated physicians and scientists, along with capable and often inspired leadership, have placed the Duke School of Medicine among the nation s best. Now,
HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
Personalised Healthcare Frequently Asked Questions
Personalised Healthcare Frequently Asked Questions Foreword In one sense, personalised healthcare is nothing new. It is what doctors have aimed to provide for their patients through the exercise of their
1. WHY ARE ELECTRONIC MEDICAL RECORDS IMPORTANT FOR PERSONALIZED MEDICINE?
THE ELECTRONIC MEDICAL RECORD: A CRITICAL ISSUE IN PERSONALIZED MEDICINE 1. WHY ARE ELECTRONIC MEDICAL RECORDS IMPORTANT FOR PERSONALIZED MEDICINE? As initially configured, electronic medical records (EMRs)
Pharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
Dr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
Graduate Program Objective #1 Course Objectives
1 Graduate Program Objective #1: Integrate nursing science and theory, biophysical, psychosocial, ethical, analytical, and organizational science as the foundation for the highest level of nursing practice.
How Can Institutions Foster OMICS Research While Protecting Patients?
IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice
Relationships of Complexity Research and Futures Studies. Dr. Auli Keskinen EXYSTENCE Seminar Nov 2004
Relationships of Complexity Research and Futures Studies Dr. Auli Keskinen EXYSTENCE Seminar Nov 2004 Dr. Auli Keskinen Director, R&D Sustainable Development & Information Society & Futures Research Ministry
Anforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research
Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from
Following are detailed competencies which are addressed to various extents in coursework, field training and the integrative project.
MPH Epidemiology Following are detailed competencies which are addressed to various extents in coursework, field training and the integrative project. Biostatistics Describe the roles biostatistics serves
Big Data Trends A Basis for Personalized Medicine
Big Data Trends A Basis for Personalized Medicine Dr. Hellmuth Broda, Principal Technology Architect emedikation: Verordnung, Support Prozesse & Logistik 5. Juni, 2013, Inselspital Bern Over 150,000 Employees
Technology funding opportunities at the National Cancer Institute
Technology funding opportunities at the National Cancer Institute Through the Cancer Diagnosis Program http://cancerdiagnosis.nci.nih.gov/index.html Avraham Rasooly Ph.D. National Cancer Institute, Cancer
Personalized medicine in China s healthcare system
Personalized medicine in China s healthcare system Jingmin Kan, Sam Linsen Netherlands office for Science and Technology, Guangzhou and Shanghai, China Content PERSONALIZED MEDICINE 2 FOCUS AT THE INDIVIDUAL
PART I. SECTION 1. The legislature finds that an estimated. 128,000,000 Americans suffer from the crippling economic and
HOUSE OF REPRESENTATIVES TWENTY-FOURTH LEGISLATURE, 2007 STATE OF HAWAII A BILL FOR AN ACT RELATING TO MEDICAL RESEARCH. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: PART I SECTION 1. The legislature
Bioethics Education in Professional Science Master s Programs at California State University Channel Islands
ETHICS AND THE PSM Bioethics Education in Professional Science Master s Programs at California State University Channel Islands Ching-Hua Wang, M.D., Ph.D., Director of MS Biotechnology and Bioinformatics
Human Health Sciences
Human Health Sciences WITH PLYMOUTH UNIVERSITY DISCOVER MORE If you would like to visit Plymouth and meet our staff, then why not come along to one of our open days. Human Health Sciences WITH PLYMOUTH
From Data to Foresight:
Laura Haas, IBM Fellow IBM Research - Almaden From Data to Foresight: Leveraging Data and Analytics for Materials Research 1 2011 IBM Corporation The road from data to foresight is long? Consumer Reports
Stem Cells and Hope for Patients
Stem Cells and Hope for Patients by Maureen Condic, Ph.D. Most Americans know someone afflicted with an incurable medical condition. The possibility of stem cell cures has given hope to many who face such
Welcome Address by the. State Secretary at the Federal Ministry of Education and Research. Dr Georg Schütte
Welcome Address by the State Secretary at the Federal Ministry of Education and Research Dr Georg Schütte at the "Systems Biology and Systems Medicine" session of the World Health Summit at the Federal
Donna J. Dean, Ph.D. October 27, 2009 Brown University
Building Connections with NIH Program Officers: Myths and Realities Donna J. Dean, Ph.D. October 27, 2009 Brown University Funding Agencies Federal Agencies Focused on Biomedical Research s of Health (NIH)
One Research Court, Suite 200 Rockville, MD 20850 www.ctisinc.com Tel: 301.948.3033 Fax: 301.948.2242
TRANSFORMATION OF HEALTH INDUSTRY THROUGH PERFORMANCE PYRAMID: Providing Excellent End-to-End Healthcare to the Population with a 30% Reduction in Cost and Time. Introduction The American health industry
Degree Level Expectations, Learning Outcomes, Indicators of Achievement and the Program Requirements that Support the Learning Outcomes
Department/Academic Unit: Pathology and Molecular Medicine Degree Program: PhD Degree Level Expectations, Learning Outcomes, Indicators of Achievement and the Program Requirements that Support the Learning
FACULTY OF MEDICAL SCIENCE
Doctor of Philosophy in Biochemistry FACULTY OF MEDICAL SCIENCE Naresuan University 73 Doctor of Philosophy in Biochemistry The Biochemistry Department at Naresuan University is a leader in lower northern
The ethics of stem cell research and treatment
The ethics of stem cell research and treatment Bernard Lo, M.D. March 12, 2009 1 hesc: ethical controversies Moral status of embryo? Clearly a potential person Some believe a person with rights Is hesc
Big Data Analytics Driving Healthcare Transformation
Big Data Analytics Driving Healthcare Transformation Greg Caressi SVP Healthcare & Life Sciences November, 2014 Six Big Themes for the New Healthcare Economy Themes Modernizing Care Delivery Clinical practice
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:
TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES
TRANSATLANTIC CONSUMER DIALOGUE WASHINGTON MEETING, 10-12 FEBRUARY 2000 TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES The Commission Services
Grand V Challenge We must improve human health, nutrition and wellness of the U.S. population
Grand V Challenge We must improve human health, nutrition and wellness of the U.S. population 1 Current Health Challenges Large health care costs(estimates range from $2.5 to $3 trillion in 2008 and 2009)
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization
Roche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine
Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine Graduate Certificate in Metabolic & Nutritional Medicine Graduate Certificate Metabolic & Nutritional Medicine Purpose
Why Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
Online MPH Program Supplemental Application Handbook
Online MPH Program Supplemental Application Handbook Table of Contents Online MPH Supplemental Application Handbook Completing & Submitting the Supplemental Application 2 Eligible Previous Public Health
Big Data and Predictive Medicine
Big Data and Predictive Medicine Prof., PhD University Hospital Zurich University of Zurich Higher School of Economics Moscow, Russia June 19, 2014 Progress toward data-based predictive medicine! Why is
Research Agenda for General Practice / Family Medicine and Primary Health Care in Europe Summary EGPRN
Research Agenda for General Practice / Family Medicine and Primary Health Care in Europe Summary EGPRN EUROPEAN GENERAL PRACTICE RESEARCH NETWO RK EGPRN is a network organisation within WONCA Region Europe
ASPH Education Committee Master s Degree in Public Health Core Competency Development Project
ASPH Education Committee Master s Degree in Public Health Core Competency Development Project Version 2.3 Word Format Domains and Competencies Only May 2007 Discipline-specific Competencies A. BIOSTATISTICS
Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)
Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and
Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020
Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Lucia Monaco Horizon 2020 Advisory Group, Societal Challenges 1: Health, Demographic Change and Wellbeing Seminario:
Introduction. John Auerbach, Commissioner, Massachusetts Department of Public Health, at the June 2010 forum
Introduction In 2007, a report written for the Boston Foundation by the New England Healthcare Institute, titled The Boston Paradox: Lots of Health Care, Not Enough Health, was the first view of Bostonians
BARACK OBAMA S PLAN FOR A HEALTHY AMERICA:
BARACK OBAMA S PLAN FOR A HEALTHY AMERICA: Lowering health care costs and ensuring affordable, high-quality health care for all The U.S. spends $2 trillion on health care every year, and offers the best
TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
Causation in Systems Medicine: Epistemological and Metaphysical Challenges
Causation in Systems Medicine: Epistemological and Metaphysical Challenges Jon Williamson 8 January 2015 EBM+ workshop, Kent Contents 1 Systems Medicine 2 Epistemological Challenges for Systems Medicine
Attacking the Biobank Bottleneck
Attacking the Biobank Bottleneck Professor Jan-Eric Litton BBMRI-ERIC BBMRI-ERIC Big Data meets research biobanking Big data is high-volume, high-velocity and highvariety information assets that demand
Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics
Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics Response by the Genetic Interest Group Question 1: Health
Ethical Issues Surrounding the Conduct of Pediatric Clinical Studies
Ethical Issues Surrounding the Conduct of Pediatric Clinical Studies Karsten A. Holm Saint Joseph s University Graduate Ethics Paper Competition, Fall 2013 (Word Count 3000) 1 Introduction The ethical
Health Informatics Research and Development in Europe
Workshop on Health Informatics Research and Development, London, 18 July 2002 Health Informatics Research and Development in Europe Sofie Nørager European Commission Information Society Technologies Program
Advanced Nursing Research in Critical Care
12 th Congress of the World Federation of Societies of Intensive and Critical Care Medicine Advanced Nursing Research in Critical Care Yeonsoo Jang RN, PhD. Assistant Professor Yonsei University College
Select Healthcare Themes and Investment Opportunities
Select Healthcare and Demographic Shift Towards Older Population There were around 40 million Americans that are 65 and older in 2010 2 The population of seniors 65 and older is set to grow to 55 million
GLOBAL ACCESS LICENSING FRAMEWORK
GLOBAL ACCESS LICENSING FRAMEWORK Every university-developed technology with potential for further development into a drug, vaccine, or medical diagnostic should be licensed with a concrete and transparent
Cellular Wireless technology: Creating a link between people and the healthcare community
Cellular Wireless technology: Creating a link between people and the healthcare community Introduction Demands on health-care systems worldwide have increased to the point where the delivery and cost of
Health Authority Abu Dhabi
Health Authority Abu Dhabi Document Title: Policy Scope of Practice for Registered Nurses Document Ref. Number: PPR/HC/EX/P0004/07 - A Version 0.9 Approval Date: May 2007 Effective Date: May 2007 Last
Subdomain Weight (%)
CLINICAL NURSE LEADER (CNL ) CERTIFICATION EXAM BLUEPRINT SUBDOMAIN WEIGHTS (Effective June 2014) Subdomain Weight (%) Nursing Leadership Horizontal Leadership 7 Interdisciplinary Communication and Collaboration
Arthritis Foundation Position Statement on Biosimilar Substitution
Arthritis Foundation Position Statement on Biosimilar Substitution The Affordable Care Act creates a regulatory pathway for the approval of a new generation of biologic medications called biosimilars.
CCR Biology - Chapter 9 Practice Test - Summer 2012
Name: Class: Date: CCR Biology - Chapter 9 Practice Test - Summer 2012 Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Genetic engineering is possible
Research for a Healthy Life RESEARCH
Research into Prevention and Nutrition - Action Plan Research for a Healthy Life RESEARCH Research into Prevention and Nutrition - Action Plan Research for a Healthy Life RESEARCH Contents 1 Contents
FACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
Suzanne Bennett Johnson 2012 APA President sbjohnson@apa.org
Medicine s Paradigm Shift: The Case for Integrated Care Suzanne Bennett Johnson 2012 APA President sbjohnson@apa.org Presentation Overview The biomedical model and its legacy Increased life expectancy
Policy statement. Stem cell research
Policy statement Stem cell research Introduction For some people who survive a heart attack, the damage to their heart muscle can lead to debilitating heart failure, for which there is no cure. Nearly
EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases
EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases EURORDIS - the European Organisation for Rare Diseases represents 310 rare disease organisations from 34
Action Plan: National Program 107 Human Nutrition 2014 2019
Action Plan: National Program 107 Human Nutrition 2014 2019 Goal: National Program (NP) 107, Human Nutrition, will improve the nutrition and health of the American people by enhancing the quality of the
Test Content Outline Effective Date: October 25, 2014. Medical-Surgical Nursing Board Certification Examination
Board Certification Examination There are 175 questions on this examination. Of these, 150 are scored questions and 25 are pretest questions that are not scored. Pretest questions are used to determine
Academic Health Center Six-Year Strategic Plan October 20, 2000
Goal 1: Create and Prepare the New Health Professionals for Minnesota Strategic Objectives 1.0 Develop and implement interdisciplinary health professional education opportunities that: Emphasize the core
Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics: Outcome Indicators
Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics: Outcome Indicators Introduction The Outcome Indicators are an adjunct to the Essential Nursing Competencies and Curricula
The MPH. ability to. areas. program. planning, the following. Competencies: research. 4. Distinguish. among the for selection
MPH COMPETENCIES The MPH competencies are based on those approved by the Association of Schools of Public Health (ASPH) in 2006. By graduation, all MPH students must demonstrate the ability to apply public
Review of CBER's Current and Planned Post-marketing Safety Practices
Review of CBER's Current and Planned Post-marketing Safety Practices Robert Ball MD, MPH, ScM Director, Office of Biostatistics and Epidemiology (OBE), Center for Biologics Evaluation and Research (CBER),
October 17, 2005. Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892
October 17, 2005 Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892 Dear Dr. Zerhouni: The undersigned nonprofit medical and scientific societies
Ramazzini days 2015. LT Budnik
Advocating exposure assessment in postgraduate training M Albin, P Scheepers, L Casteleyn, C Bolognesi, K van Damme, X Baur, T Sigsgaard, L Budnik Ramazzini days 2015 LT Budnik Focus on various aspects
Prognosis for Healthcare: The Future of Medicine
Prognosis for Healthcare: The Future of Medicine Bruce M. Cohen, M.D., Ph.D. Director, Frazier Research Institute, McLean Hospital President and Psychiatrist in Chief Emeritus, McLean Hospital Robertson-Steele
If you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However
Course Requirements for the Ph.D., M.S. and Certificate Programs
Health Informatics Course Requirements for the Ph.D., M.S. and Certificate Programs Health Informatics Core (6 s.h.) All students must take the following two courses. 173:120 Principles of Public Health
Position on the Private Healthcare System (as of November 2015)
Candidate Position on the Private Healthcare System (as of November 2015) Clinton Defends the ACA Sept. 23, 2015 Plan outlines Clinton s proposals: Lower Deductibles, Coinsurance, and Co Pays Up to three
Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
We decided to start with the New Basics!
What employees think of healthcare Confusing Uhh, What?... Frustrating I give up! We decided to start with the New Basics! Agenda City of Dallas Challenges (what caused our approach to benefits to change)
AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
IMPLEMENTING BIG DATA IN TODAY S HEALTH CARE PRAXIS: A CONUNDRUM TO PATIENTS, CAREGIVERS AND OTHER STAKEHOLDERS - WHAT IS THE VALUE AND WHO PAYS
IMPLEMENTING BIG DATA IN TODAY S HEALTH CARE PRAXIS: A CONUNDRUM TO PATIENTS, CAREGIVERS AND OTHER STAKEHOLDERS - WHAT IS THE VALUE AND WHO PAYS 29 OCTOBER 2015 DR. DIRK J. EVERS BACKGROUND TreatmentMAP
The Department of Public Health Sciences
The Department of Public Health Sciences Who we are at the U.Va. School of Medicine Committed to improving population health and clinical care The Department of Public Health Sciences, established in 1995,
Cancer Genomics: What Does It Mean for You?
Cancer Genomics: What Does It Mean for You? The Connection Between Cancer and DNA One person dies from cancer each minute in the United States. That s 1,500 deaths each day. As the population ages, this
Some Biomedical Informatics Programs at NIBIB and NIH
Some Biomedical Informatics Programs at NIBIB and NIH BIBM 2009 November 3, 2009 Zohara Cohen, PhD of Biomedical Imaging & Bioengineering NIH, DHHS Training Grants and Fellowships: Career Development Awards
Clinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
Health Science Career Field Allied Health and Nursing Pathway (JM)
Health Science Career Field Allied Health and Nursing Pathway (JM) ODE Courses Possible Sinclair Courses CTAG Courses for approved programs Health Science and Technology 1 st course in the Career Field
PROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE
PROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE Joint study by the WHO, WIPO and WTO Secretariats Outline and overview The WHO, WIPO and the
M.Sc. in Nano Technology with specialisation in Nano Biotechnology
M.Sc. in Nano Technology with specialisation in Nano Biotechnology Nanotechnology is all about designing, fabricating and controlling materials, components and machinery with dimensions on the nanoscale,
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood Supreme Council of Health Department of Research Guidance Regarding Research Involving Human Embryonic
executive summary Scope Aim and targeted readership
executive summary Scope The development, evaluation and introduction of medical innovations and technologies in general and innovative medical devices in particular are considered an increasingly important
646 HEALTH CARE POLICY IN THE U.S.: DEVELOPMENT, IMPACTS AND IMPLICATIONS FOR NURSES
Graduate Courses: Master s Courses (NURS) AY 2012-13 (Effective August 2012) Professional Core 646 HEALTH CARE POLICY IN THE U.S.: DEVELOPMENT, IMPACTS AND IMPLICATIONS FOR NURSES (3). This course examines